| Dr Ripal H Patel, MD | |
|
700 Scott And White Dr, College Station, TX 77845-6441 | |
| (979) 207-0100 | |
| Not Available |
| Full Name | Dr Ripal H Patel |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 700 Scott And White Dr, College Station, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114217338 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | P8611 (Texas) | Secondary |
| 207P00000X | Emergency Medicine | 308207 (Louisiana) | Secondary |
| 207P00000X | Emergency Medicine | 55160 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lea Regional Medical Center | Hobbs, NM | Hospital |
| Chi Health St. Francis | Grand island, NE | Hospital |
| Valley Baptist Medical Center- Brownsville | Brownsville, TX | Hospital |
| Vhs Harlingen Hospital Company Llc | Harlingen, TX | Hospital |
| Baylor Scott & White Medical Center- College Stati | College station, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospitalist Medicine Physicians Of New Mexico - Clovis Llc | 0345618849 | 29 |
| Midwest Emergency Grand Island Inc | 1153677828 | 12 |
News Archive
CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.
Researchers at the University of Pennsylvania School of Medicine have helped develop a technique in animal models for using the abdominal cavity to exchange gas, supplementing the function normally performed by the lungs.
GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency's development of an awareness campaign for the Children's Neuroblastoma Cancer Foundation.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
› Verified 4 days ago
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.
Researchers at the University of Pennsylvania School of Medicine have helped develop a technique in animal models for using the abdominal cavity to exchange gas, supplementing the function normally performed by the lungs.
GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency's development of an awareness campaign for the Children's Neuroblastoma Cancer Foundation.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
› Verified 4 days ago
| Entity Name | Island Medical Loe Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457636706 PECOS PAC ID: 3274700323 Enrollment ID: O20120113000095 |
News Archive
CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.
Researchers at the University of Pennsylvania School of Medicine have helped develop a technique in animal models for using the abdominal cavity to exchange gas, supplementing the function normally performed by the lungs.
GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency's development of an awareness campaign for the Children's Neuroblastoma Cancer Foundation.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
› Verified 4 days ago
| Entity Name | App Of New Mexico Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891169942 PECOS PAC ID: 7416259445 Enrollment ID: O20160108000220 |
News Archive
CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.
Researchers at the University of Pennsylvania School of Medicine have helped develop a technique in animal models for using the abdominal cavity to exchange gas, supplementing the function normally performed by the lungs.
GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency's development of an awareness campaign for the Children's Neuroblastoma Cancer Foundation.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
› Verified 4 days ago
| Entity Name | Curry Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508223082 PECOS PAC ID: 1759687064 Enrollment ID: O20160314000822 |
News Archive
CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.
Researchers at the University of Pennsylvania School of Medicine have helped develop a technique in animal models for using the abdominal cavity to exchange gas, supplementing the function normally performed by the lungs.
GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency's development of an awareness campaign for the Children's Neuroblastoma Cancer Foundation.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
› Verified 4 days ago
| Entity Name | Hospitalist Medicine Physicians Of New Mexico - Clovis Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477031094 PECOS PAC ID: 0345618849 Enrollment ID: O20221114002666 |
News Archive
CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.
Researchers at the University of Pennsylvania School of Medicine have helped develop a technique in animal models for using the abdominal cavity to exchange gas, supplementing the function normally performed by the lungs.
GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency's development of an awareness campaign for the Children's Neuroblastoma Cancer Foundation.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
› Verified 4 days ago
| Entity Name | Nes Arizona Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285163121 PECOS PAC ID: 2163737206 Enrollment ID: O20230803001059 |
News Archive
CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.
Researchers at the University of Pennsylvania School of Medicine have helped develop a technique in animal models for using the abdominal cavity to exchange gas, supplementing the function normally performed by the lungs.
GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency's development of an awareness campaign for the Children's Neuroblastoma Cancer Foundation.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ripal H Patel, MD Po Box 844658, Dallas, TX 75284-4658 Ph: (254) 724-8800 | Dr Ripal H Patel, MD 700 Scott And White Dr, College Station, TX 77845-6441 Ph: (979) 207-0100 |
News Archive
CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.
Researchers at the University of Pennsylvania School of Medicine have helped develop a technique in animal models for using the abdominal cavity to exchange gas, supplementing the function normally performed by the lungs.
GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency's development of an awareness campaign for the Children's Neuroblastoma Cancer Foundation.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
› Verified 4 days ago
Dr. Chet Dean Schrader, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 | |
Dr. Kenneth Wilson Conner Iv, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 Fax: 979-207-2161 | |
Ann Marie Reed, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: Texas A And M University A P Beutel Health Ctr, Tamu 1264, College Station, TX 77843 Phone: 979-458-8272 Fax: 979-458-8352 | |
Scott Kimball, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1604 Rock Prairie Rd, College Station, TX 77845 Phone: 979-764-5100 | |
Garry Lynn Gore, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1604 Rock Prairie Rd, College Station, TX 77845 Phone: 979-764-5100 | |
Angela Yang Polansky, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 |